Xiangyan Ruan1, Ying Zhang, Alfred O Mueck, Marina Willibald, Harald Seeger, Tanja Fehm, Sara Brucker, Hans Neubauer. 1. 1Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China 2Department of Women's Health, University Hospital and Faculty of Medicine of the Eberhard Karls University Tuebingen, Tuebingen, Germany 3Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Abstract
OBJECTIVE: Expression of progesterone receptor membrane component 1 (PGRMC1) has been shown to be higher in breast cancer than normal tissue. We have previously shown that certain progestogens strongly stimulate proliferation of breast cancer cells overexpressing PGRMC1, and therefore hypothesize that PGRMC1 may play a critical role in breast cancer progression. Because little information is available if expression of PGRMC1 is also associated with worse prognosis for breast cancer patients, in this study we investigated the clinicopathologic significance of PGRMC1 expression in breast cancer tissue. METHODS: Expression of PGRMC1 was analyzed by immunohistochemical staining of primary tumor tissues obtained from 69 breast cancer patients. A labeling score was developed, and results were correlated with tumor size, lymph node metastasis, and clinical outcome. RESULTS: Overexpression of PGRMC1 is correlating with larger tumor size and lymph node metastasis. Kaplan-Meier survival curves indicate that patients with PGRMC1 tumors have poorer disease-free and overall survival independent from the estrogen receptor status than breast cancer patients with PGRMC1 tumors. CONCLUSIONS: Our findings suggest that the expression of PGRMC1 might be useful for predicting prognosis in patients with breast cancer.
OBJECTIVE: Expression of progesterone receptor membrane component 1 (PGRMC1) has been shown to be higher in breast cancer than normal tissue. We have previously shown that certain progestogens strongly stimulate proliferation of breast cancer cells overexpressing PGRMC1, and therefore hypothesize that PGRMC1 may play a critical role in breast cancer progression. Because little information is available if expression of PGRMC1 is also associated with worse prognosis for breast cancerpatients, in this study we investigated the clinicopathologic significance of PGRMC1 expression in breast cancer tissue. METHODS: Expression of PGRMC1 was analyzed by immunohistochemical staining of primary tumor tissues obtained from 69 breast cancerpatients. A labeling score was developed, and results were correlated with tumor size, lymph node metastasis, and clinical outcome. RESULTS: Overexpression of PGRMC1 is correlating with larger tumor size and lymph node metastasis. Kaplan-Meier survival curves indicate that patients with PGRMC1 tumors have poorer disease-free and overall survival independent from the estrogen receptor status than breast cancerpatients with PGRMC1 tumors. CONCLUSIONS: Our findings suggest that the expression of PGRMC1 might be useful for predicting prognosis in patients with breast cancer.
Authors: Hans Neubauer; Marina Ludescher; Hannah Asperger; Nadia Stamm; Berthold Gierke; Michael Pawlak; Ute Hofmann; Ulrich M Zanger; Annamaria Marton; Robert L Katona; Andrea Buhala; Csaba Vizler; Jan-Philipp Cieslik; Eugen Ruckhäberle; Dieter Niederacher; Tanja Fehm Journal: Breast Cancer Res Date: 2020-07-13 Impact factor: 6.466